Cassidy's new plan to overhaul 340B: Rebates, contract pharmacy limits and more changes

By Dave Muoio – After years of investigation, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee has released his take on new legislation to reform the controversial 340B Drug Pricing Program. Sen. Bill Cassidy, R-Louisiana, unveiled a legislative discussion draft that would stand as the first statutory update to the subsidy program in 15 years if introduced and signed into law. Read Full Article...

HVBA Article Summary

1. Proposed Shift to Rebates and Added Reporting Requirements: The discussion draft would allow drug manufacturers to provide discounts either upfront or as rebates after claims data submission, a structure supporters say could reduce duplicate discounts and diversion. It would also require participating nonprofits to regularly report detailed information on 340B-related revenues, costs and eligibility. Supporters argue these measures would increase transparency and oversight. Hospitals, however, have historically opposed rebate-style models and expanded reporting, citing administrative burden and cash flow concerns.

2. Limits on Contract Pharmacies and Clearer Definitions: The draft introduces new statutory definitions for terms such as “patient” and clarifies rules governing contract pharmacies and child sites, areas that have prompted significant litigation. Notably, hospitals would be limited to five contract pharmacies, excluding mail-order pharmacies. These provisions aim to address concerns from drugmakers about program misuse and margin expansion. Providers warn that tighter definitions and limits could restrict how safety-net hospitals deliver discounted drugs to vulnerable populations.

3. Political Context and Financial Stakes: The 340B program accounted for $81 billion in drug purchases in 2024, representing more than 16% of total U.S. drug spending, underscoring its scale and influence. Cassidy’s proposal follows a multi-year investigation launched in 2023, with findings informing the current draft legislation. Lawmakers and the administration have shown increased interest in oversight as healthcare spending remains a prominent policy issue. Stakeholder feedback is being solicited through late August, and hospital groups have signaled plans to push for changes before any bill is formally introduced.

House panel OKs hospital price transparency bills

By Allison Bell – Republicans and Democrats on the House Energy & Commerce Health Subcommittee joined Thursday to approve a total of 15 health care bills by voice votes. The Lower Costs, More Transparency Act of 2026, the Premium Transparency Act, the Prior Authorization Accountability Act and the Prices on the Wall Act of 2026 are approved bills that could directly affect employer-sponsored health plans. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Broad Bipartisan Support for Transparency Measures: Members of the House Energy & Commerce Health Subcommittee from both parties approved 15 health care bills during a markup session. The measures advanced by voice vote, indicating no recorded opposition at that stage. Lawmakers from both sides framed the legislation as a way to address persistent concerns about health care costs and opacity. The bills now move forward with the potential for consideration by the full House.

2. New Requirements for Hospitals and Health Plans: Several of the approved bills would impose more detailed disclosure obligations on hospitals and insurers. Proposals include standardizing hospital price file formats, requiring insurers and employer-sponsored plans to disclose prior authorization program operations, and mandating that hospitals post discounted cash or median self-pay prices for shoppable services. Another measure would require issuers of fully insured group plans to release detailed overhead cost information. Together, these provisions aim to increase visibility into pricing and administrative practices affecting employer-sponsored coverage.

3. Debate Over Practical Impact on Patients: While lawmakers generally supported greater transparency, some raised concerns about how posted prices might be interpreted. One Democratic member argued that displaying hospital prices publicly could confuse patients because listed amounts may not reflect what insured individuals ultimately pay. Supporters countered that clearer price information would promote competition and empower consumers to make informed decisions. Despite reservations, the transparency-focused bills advanced without audible opposition during the markup session.

Florida probes CVS Health in latest crackdown on PBMs

By Chad Van Alstin – Florida is the latest state to launch an investigation into the business practices of pharmacy benefit managers (PBMs), specifically in this case Caremark, part of CVS Health. Announced Wednesday, state Attorney General James Uthmeier said a “civil investigative demand” has been sent to CVS, seeking to examine the scope of anticompetitive business practices the company may be engaged in, both in its role as a middleman in the distribution of pharmaceutical drugs and through its retail chain of pharmacy stores. Read Full Article...

HVBA Article Summary

1. Focus on Potential Self-Preferencing and Anticompetitive Conduct: Florida’s attorney general is examining whether CVS is using its dual role as a pharmacy benefit manager and retail pharmacy operator to advantage its own stores. The investigation centers on allegations that independent pharmacies may face stricter audits and less favorable reimbursement for the same prescriptions. Officials are also reviewing whether CVS steers patients and health plans to its own pharmacies through discounts and rebates not equally available to competitors. If proven, such conduct could violate state laws governing competition and fair market practices.

2. Market Dominance and Vertical Integration Concerns: The announcement highlights that the three largest PBMs—Express Scripts, Optum Rx and Caremark—control about 80% of U.S. prescriptions, underscoring the concentrated nature of the market. CVS’s position is distinctive because it operates roughly 9,000 retail pharmacies nationwide, including about 800 in Florida, alongside its PBM business. State officials have raised concerns that this vertical integration may contribute to “pharmacy deserts” if smaller, independent stores are pushed out of business. Reduced competition in rural or underserved areas could limit patient access to medications and pharmacy services.

3. Part of a Broader National Regulatory Push: Florida’s probe aligns with actions in other states such as Arkansas and Tennessee, which have passed laws restricting PBMs from owning retail pharmacies. Those laws are currently being challenged in court by major PBMs, reflecting an ongoing legal battle over industry structure. Additional states including Virginia, New York, Oklahoma and Texas are considering similar measures aimed at tightening oversight. In Florida’s case, CVS has been ordered to provide extensive documentation on reimbursement rates and contracts by late July 2026, though no formal wrongdoing has yet been alleged.

Two Studies Link GLP-1 Use to Lower Breast Cancer Risk

By Will Pass – GLP-1 receptor agonists (GLP-1 RAs) are associated with reduced incidence of breast cancer among women with overweight or obesity, according to two observational studies. One found that GLP-1 RA users had a roughly 30% lower incidence of breast cancer than was seen in matched nonusers. The smaller of the two, which followed more than 80,000 women at high risk for breast cancer, found a more modest 16% reduction. Read Full Article...

HVBA Article Summary

1. Large Screening Study Shows Significant Risk Reduction: In an analysis of 111,646 screened women aged 45-80 with a BMI of 25 or higher, those prescribed GLP-1 receptor agonists had lower rates of breast cancer than matched nonusers. After adjusting for demographic and clinical variables, use of these medications was associated with 30% lower odds of developing breast cancer. Investigators noted that GLP-1 users in the study had more underlying health conditions, which could have biased results against finding a benefit rather than exaggerating one.

2. High-Risk Cohort Demonstrates More Modest Benefit: A separate study of 80,480 women with obesity who were already at elevated risk for breast cancer found a 16% lower incidence among GLP-1 RA users compared with matched controls. This analysis drew on a large global database and included women with genetic risk factors, dense breasts, or prior high-risk lesions. Researchers emphasized that the retrospective design makes the findings hypothesis-generating rather than practice-changing.

3. Mechanisms and Clinical Implications Remain Uncertain: Experts suggest that weight loss is likely a key driver of the observed risk reduction, given the established link between obesity and postmenopausal breast cancer. GLP-1 RAs may also influence cancer-related pathways through effects on insulin resistance, inflammation, adiponectin levels, and possibly estrogen production. However, specialists stress that randomized controlled trials are needed before these drugs could be recommended specifically for breast cancer prevention.

The most impactful benefits for men right now

By Lee Hafner – This year's Men's Health Month produced data and expert insight on current challenges men face, and how employers can provide meaningful support. From their physical, mental and financial health to family caregiving responsibilities to work, men have a lot to manage. Yet they often delay or neglect their own care and underutilize benefits, said Reza Amin, CEO of digital men's health clinic Bastion Heath, leading to unnecessarily negative outcomes. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Bridging the gap between coverage and care: Although more than 150 million Americans receive health insurance through their employer, experts say many men struggle to translate that coverage into actual care. Fragmented benefit pathways, unclear screening guidelines and limited targeted outreach contribute to underuse. Leaders are encouraged to redesign benefits and communication strategies so they are easier to navigate and culturally responsive. A more proactive structure could help reduce avoidable long-term health issues.

2. Preventive and mental health support require normalization and clarity: A significant share of men skip recommended medical care, with 42% reporting they avoided care in the past year and many citing cost concerns. Employers can address this by clearly communicating which preventive services are covered at low or no cost and encouraging time off for screenings. At the same time, loneliness and increased mental health leave among younger men point to a need for stronger emotional well-being support. Expanding employee assistance programs and reducing stigma around mental health can improve both outcomes and workplace productivity.

3. Financial strain and caregiving pressures are rising: Financial stress remains a primary driver of anxiety for many workers, making consistent communication about financial wellness benefits increasingly important. Employers that take a holistic approach to financial health may help stabilize employees’ overall well-being. Meanwhile, caregiving responsibilities are expanding among male employees: in a survey of 1,000 men, 1 in 3 reported caring for a loved one, and some experienced career setbacks as a result. Organizations that formally recognize and support caregivers may be better positioned to retain talent and reduce hidden workforce strain.

Data breach on healthcare AI vendor exposes records from 1.4M patients

By Chad Van Alstin – Last week, HealthExec reported on a data breach at a healthcare AI company that resulted in personal data from its hospital and payer clients being exposed to hackers. This week, a filing with the federal government provided details on how many patients were impacted. Read Full Article...

HVBA Article Summary

1. Scope of the Breach Confirmed by Federal Filing: A report to the U.S. Department of Health and Human Services’ Office of Civil Rights determined that 1,396,519 individuals were affected by the incident. The disclosure was formally filed on June 5, adding the event to the federal healthcare data breach tracker. This confirmation provides a clearer picture of the scale of the intrusion compared to earlier reports. The breach ranks among the larger healthcare cybersecurity incidents reported this year.

2. Sensitive Health and Personal Data Compromised: The exposed information included protected health details such as treatment information, along with names, dates of birth, contact information, Social Security numbers and insurance data. Such a combination of medical and identifying information can increase risks related to identity theft and fraud. Xsolis stated that it has not found evidence that the stolen data has been misused. To support affected individuals, the company is offering complimentary identity theft protection and credit monitoring services.

3. Phishing Attack Vector and Response Efforts: Xsolis attributed the breach to a targeted phishing attack that enabled unauthorized access to its network. The intrusion was detected two days after hackers initially gained entry, and the company engaged a third-party cybersecurity firm to investigate and strengthen safeguards. No hacking group has claimed responsibility, and the data has not been observed for sale on the dark web. Hospitals and health systems that use Xsolis’ technology are responsible for notifying impacted patients, with at least one provider already issuing alerts.

Employers want AI benefits support, but workers aren't sold yet

By Alan Goforth – More than 8 in 10 employers are interested in using artificial intelligence to help workers better understand their benefits. However, only 58% of employees say they would use AI for this purpose, and just 24% say they do so today. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Trust and privacy concerns are slowing adoption: Both employers (49%) and employees (52%) identify privacy and security as primary barriers to AI use in benefits administration. Employees are also twice as likely as employers to say they simply do not trust AI overall (25% versus 12%). Additional concerns include potential inaccuracies, ethical implications and fears about job displacement. These perceptions suggest that technical capability alone will not drive adoption without stronger trust-building efforts.

2. Usage differs across workforce segments: Adoption is uneven depending on employee role and work structure. The study found that 40% of unionized employees already use AI for benefits guidance, compared with 27% of salaried employees and 27% of sole decision-makers. These variations indicate that workplace context and job type may influence openness to AI-driven tools. Employers may need tailored communication strategies to reach segments that are less engaged.

3. Employees are willing to share data for personalization: A majority of workers (65%) say they are comfortable with their employer managing personal data for benefits purposes, with that figure rising to 75% among those in technology-related roles. Prior research from 2024 showed nearly 7 in 10 employees wanted more personalized support during open enrollment, and about 9 in 10 were willing to share personal details to receive tailored recommendations. This suggests there is underlying demand for customized guidance, even if skepticism about AI remains. Clear communication about how data is handled could help bridge the gap between interest in personalization and hesitation about AI tools.